Welcome to our dedicated page for Quidel news (Ticker: QDEL), a resource for investors and traders seeking the latest updates and insights on Quidel stock.
QuidelOrtho Corporation reports developments in in vitro diagnostics, including rapid testing, immunoassay and molecular testing, clinical chemistry, transfusion medicine and point-of-care diagnostic platforms. Company updates commonly address financial results, revenue trends, guidance, respiratory testing seasonality, international market conditions and portfolio activity across labs, cardiac, immunohematology and molecular diagnostics.
Recurring news also covers product and technology developments such as the LEX VELO System, a point-of-care molecular PCR platform with FDA 510(k) clearance and CLIA waived status for Flu A, Flu B and COVID-19 testing, as well as diagnostic education topics including syphilis screening and high-sensitivity troponin. Governance and management changes appear alongside business updates and investor conference participation.
QuidelOrtho (Nasdaq: QDEL) announced it will report financial results for its second quarter 2026, ended June 28, 2026, after the market close on Thursday, August 6, 2026. A conference call to discuss the results will begin at 2:00 p.m. PT / 5:00 p.m. ET, accessible via the Events & Presentations section of the Investor Relations page on the company’s website. Presentation materials and a replay of the call will also be made available in the same section.
QuidelOrtho (Nasdaq: QDEL) released episode 59 of its Science Bytes podcast, focused on how the U.S. drug overdose crisis is evolving and implications for toxicology testing. The episode, hosted by Josh Casey with guest Vonda McAllister, draws on new guidance from the Association for Diagnostics and Laboratory Medicine (ADLM).
Key points include three consecutive years of declining U.S. overdose deaths in 2025, persistent risks from counterfeit fentanyl-laced pills, rising polysubstance use, and emerging synthetic opioids such as nitazenes that can evade routine screening. The discussion stresses closer collaboration between laboratories and emergency departments and highlights laboratories’ role in test selection, result interpretation and supporting timely patient care decisions.
QuidelOrtho (Nasdaq: QDEL) announced that its Board Compensation Committee approved an inducement grant of restricted stock units covering 356,555 shares of common stock to Chief Financial Officer and principal financial officer Micah Young. The RSUs were granted under the 2026 Inducement Plan pursuant to Nasdaq Listing Rule 5635(c)(4).
The grant date is July 15, 2026, and the RSUs vest in three equal annual installments on each of the first three anniversaries of the grant date, subject to Mr. Young’s continued employment. The award is governed by the 2026 Inducement Plan and a related RSU agreement.
QuidelOrtho (Nasdaq: QDEL) appointed Micah Young as Chief Financial Officer, effective July 6, 2026, succeeding retiring CFO Joseph M. Busky, who will serve in an advisory role to support transition.
Young brings over two decades of medical technology finance leadership at global public companies.
QuidelOrtho (NASDAQ:QDEL) and the Allo Hope Foundation announced a collaboration to improve care for maternal red blood cell alloimmunization. The partnership focuses on education, early testing and stronger connections between labs, clinicians and families.
Starting this summer, co-produced educational materials for lab technicians and families will be distributed via both organizations’ digital channels.
QuidelOrtho (Nasdaq: QDEL) released episode 58 of its Science Bytes podcast, focusing on hemolytic disease of the fetus and newborn (HDFN), a serious condition linked to maternal alloimmunization.
The episode discusses red blood cell antibodies in pregnancy, awareness gaps, and how timely lab testing and coordinated care can improve outcomes.
QuidelOrtho (Nasdaq: QDEL) announced that its management team will participate in two June 2026 investor conferences. The company will present at the William Blair 46th Annual Growth Stock Conference on June 2 at 12:20 p.m. ET and join a fireside chat at the Jefferies Global Healthcare Conference on June 3 at 8:10 a.m. ET. Live webcasts and replays will be available in the “Events & Presentations” section of QuidelOrtho’s Investor Relations website.
QuidelOrtho (Nasdaq: QDEL) reported Q1 2026 results on May 5, 2026: total revenue $620 million, GAAP net loss $92 million, GAAP operating loss $32 million, and adjusted EBITDA $109 million. Point of Care revenue declined 34%; Labs revenue declined 5%; Immunohematology grew 8%.
The company completed the LEX Diagnostics acquisition in April, launched High-Sensitivity Troponin in the U.S., and updated full-year 2026 guidance: total revenue $2.70–2.75B and adjusted diluted EPS $1.80–2.00, reflecting China NHSA pricing draft and Middle East uncertainties.
QuidelOrtho (Nasdaq: QDEL) released episode 57 of its Science Bytes podcast on April 23, 2026, examining U.S. syphilis trends and rising congenital syphilis.
Key facts: provisional data show a second consecutive year decline in early-stage syphilis, while congenital syphilis reached nearly 4,000 cases in 2024. The episode highlights missed or late prenatal screening and recommends repeat prenatal testing, EHR prompts, and broader screening opportunities to close gaps.
TTP Group announced the sale of spin-out LEX Diagnostics to QuidelOrtho (Nasdaq: QDEL). LEX, founded 2020 from TTP innovation, developed the VELO point-of-care PCR platform.
In February 2026, VELO received FDA 510(k) clearance and CLIA waived status; positives available in as little as 6 minutes, negatives under 10 minutes.